A Prospective, Multicenter, Phase II Clinical Trial of Vorolanib in Combination With Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal. The primary endpoint is progression-free survival (PFS).

开始日期2024-08-01

申办/合作机构

四川大学华西医院（四川省国际医院）

ChiCTR2400086552 / Suspended临床1/2期IIT

Study on the Efficacy and Safety of Vorolanib Combined with Cadonilimab in the Treatment of Untreated Advanced RCC Patients

开始日期2024-07-08

申办/合作机构

中国医学科学院肿瘤医院

100 项与伏罗尼布相关的临床结果

登录后查看更多信息

100 项与伏罗尼布相关的转化医学

登录后查看更多信息

100 项与伏罗尼布相关的专利（医药）

登录后查看更多信息

项与伏罗尼布相关的文献（医药）

2024-03-01·Bioorganic chemistry

Potential oral VEGFR2 inhibitors: Treatment of wet age-related macular degeneration

Article

作者: Cheng, Maosheng ; Liu, Yaoyang ; Yang, Huali ; Hu, Dexiang ; Liu, Yang ; Zhao, Xueqi ; Xiu, Xiaomeng ; Li, Zhenli ; Wang, Hanxun ; Jia, Hongwei ; Li, Mengzhen

Wet age-related macular degeneration (w-AMD) is one of the leading causes of vision loss in industrialized countries. A large body of evidence suggests that inhibitors targeting VEGFR2 may be effective in the treatment of w-AMD. The identification of an oral VEGFR2 inhibitor for the treatment of w-AMD provides an opportunity for a route of administration other than intravitreal injection. While screening potent VEGFR2 inhibitors at the enzyme and cellular levels, ensuring the safety of the compounds was our primary strategy for screening optimal compounds. Finally, compound 16 was identified, exhibiting enhanced inhibition of VEGFR2 enzyme and proliferation of BaF3-TEL-VEGFR2 cells compared to Vorolanib. Compound 16 had a weak inhibitory effect on human Ether-a-go-go-related gene (hERG) channel currents, showing a cardiac safety profile similar to Vorolanib. Compound 16 showed no significant toxicity to human liver cell LX-2, indicating a liver safety profile similar to Vorolanib. The water solubility of compound 16 was found to be higher than that of Vorolanib when tested at pH = 7.4. In addition, compound 16 was found to inhibit VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVECs) in a dose-dependent manner by WB assay. Furthermore, the in vitro preliminary evaluation of the drug-like properties of compound 16 showed remarkable plasma stability and moderate liver microsomal stability. Based on in vivo pharmacokinetic studies in ICR mice, compound 16 exhibited acceptable oral bioavailability (F = 20.2 %). Overall, these findings provide evidence that compound 16 is a leading potential oral drug candidate for w-AMD.

2023-12-01·Molecular therapy oncolytics

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2

作者: Zhang, Yongming ; To, Kenneth K W ; Zheng, Zongheng ; Liu, Jie ; Chen, Zhen ; Fu, Liwu ; Xu, Lejia ; Huang, Jiwei ; Xi, Yun ; Wang, Fang

[This corrects the article DOI: 10.1016/j.omto.2019.12.007.].

2023-10-01·Eye (London, England)

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study.

Article

作者: Li, Xiaoxin ; Zhang, Ming ; Shen, Zhilin ; Ding, Lieming ; Lu, Fang ; Gao, Yunxia ; Xiang, Jin ; Sun, Zuhua ; Liang, Chris ; Dai, Hong ; Liu, Xiaoling ; Wang, Yang ; Liu, Kun

OBJECTIVE:

To evaluate the efficacy and safety of oral vorolanib for the treatment of neovascular (wet) age-related macular degeneration (nAMD).

METHODS:

In the dose escalation, participants received ascending doses of oral vorolanib (25-100 mg daily). In the dose expansion, participants received recommended doses (25 and 50 mg daily).

RESULTS:

Between March 15, 2015, and January 23, 2019, 41 participants were enrolled in 6 centres in China. At the data cut-off (November 14, 2019), two dose-limiting toxicities (DLTs) were observed during dose escalation (one in the 75 mg cohort and one in the 100 mg cohort). The maximum tolerated dose was not reached. Treatment-related adverse events (TRAEs) occurred in 33 (80.5%) participants, and grade 3 or higher TRAEs occurred in 12 (29.3%) participants. No fatal TRAEs were observed. Increases in the mean best-corrected visual acuity (BCVA) from baseline to Day 360 of +7.7 letters (range, -5-29; n = 41) were observed in participants who were administered vorolanib. Corresponding reductions in mean central subfield thickness (CST) and choroidal neovascularization (CNV) area at Day 360 were observed in these three groups.

CONCLUSIONS:

Oral administration of vorolanib improved visual outcomes in participants with nAMD with manageable systemic safety profiles.

264

项与伏罗尼布相关的新闻（医药）

2024-09-04

·GlobeNewswire-Health Care

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 -WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. “I am honored to welcome Fred Hassan to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. “He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future commercialization. Fred is a visionary in the industry with extensive global biopharmaceutical experience, and his analytical and strategic insights will be invaluable as we continue to make progress in bringing a potential revolutionary treatment to patients.” “It is an honor to join the EyePoint Board of Directors at such an exciting time for the Company,” said Mr. Hassan. “I am impressed by EyePoint’s progress developing safe and effective treatments for important unmet needs in retinal disease, and I look forward to working closely with the talented management team and the Board to help bring important innovations to patients who are currently underserved by today’s treatment options.” Fred Hassan has had an exceptionally distinguished career in the biopharmaceutical industry as the former CEO of three global pharmaceutical companies. He currently serves as Director of Warburg Pincus LLC, a global private equity firm. Previously, Mr. Hassan served as Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation from 2003 to 2009. Prior to joining Schering-Plough, he was Chairman and Chief Executive Officer of Pharmacia Corporation, a company that was formed as a result of the merger of Monsanto and Pharmacia and Upjohn, Inc. Mr. Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997. Mr. Hassan previously held senior leadership positions with Wyeth, which has since been acquired by Pfizer, including Executive Vice President with responsibility for its pharmaceutical and medical products businesses. He also served as a member of the Wyeth’s board from 1995 to 1997. Earlier in his career, Mr. Hassan spent a significant tenure at Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals businesses. Mr. Hassan’s past directorships include Time Warner (2001-2018), Amgen (2015-2021) and as Chairman at Bausch & Lomb (2010-2013). Mr. Hassan has been the recipient of numerous prominent awards, including being named CEO of the Year by The Financial Times and Scrip. He has chaired several prominent pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He received an MBA from Harvard Business School and a B.S. in chemical engineering from the Imperial College of Science and Technology at the University of London. Additionally, the Company announced that Anthony P. Adamis, M.D. and David Guyer, M.D. have resigned from their positions as directors on the Company’s Board due to their transition to full-time roles at Merck & Co. “On behalf of the entire Board, I would like to express my sincere gratitude to Tony and David for their outstanding service and valuable contributions to EyePoint,” said Dr. Ando. “Their strategic and scientific insights helped shape our product development pipeline and clinical strategies. EyePoint has certainly benefited from their substantial industry insight and experience.” About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and diabetic macular edema (DME). EyePoint expects to randomize patients for inclusion in pivotal Phase 3 clinical trials in wet AMD in 2024. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for EYP-1901 (DURAVYU™) in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME); the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals including potential U.S. Food and Drug Administration (FDA) regulatory approval of DURAVYU and EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; the success of Durasert® as a drug delivery platform in FDA approved products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina TartagliaPrecision AQ (formerly Stern IR)Direct: 212-698-8700christina.tartaglia@sternir.com Media Contact: Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com

高管变更临床2期临床3期

2024-08-30

·佰傲谷BioValley

老牌眼科药企被警告cGMP违规

FDA公布了其发给EyePoint 公司的一封警告信，信中主要针对EyePiont的Yutiq存在的生产问题。 FDA指出，在生产、加工、包装以及储存等环节不符合cGMP规定，要求EyePoint聘请第三方顾问在15个工作日内，针对其指出的生产问题给出解决方案。多个cGMP生产缺陷 Yutiq是一种缓释氟轻松丙酮酯玻璃体内植入物，活性成分为—氟轻松丙酮酯，一类人工合成的皮质类固醇。Yutiq经单次植入后，在36个月时间内，持续释放共计0.18mg的氟轻松。 2018年10月，Yutiq获得FDA批准上市，用于治疗累及眼后段的慢性非感染性葡萄膜炎。2022年6月，Yutiq在国内获批上市，是国内首个完全基于"真实世界研究数据"获批上市的新药。今年2月，FDA对EyePoint位于美国watertown的工厂进行了生产现场检查，并在今年7月发出了这份警告信。 FDA在信中指出，EyePoint未能对不同批次Yutiq之间差异的原因进行彻底调查，如对某些批次的药芯异常释放率未能进行调查，并采取适当的干预措施，公司也没有跟进调查，以确保其他批次不受类似影响。 EyePoint未能建立和遵守其生产和过程控制程序，FDA检查期间，生成了多个统计工艺控制图，发现了四个之前未被发现的不良趋势。 FDA在警告信中还指出人工目检中存在的问题，该公司缺乏对加工（包装)重大缺陷的识别和舍弃。与国内企业深度合作 EyePoint是一家美国眼科制药公司，成立于2000年。 EyePoint拥有Yutiq和Duravyu两款上市产品，Duravyu是一种生物可降解的缓释抗炎药物，2018年被FDA批准用于治疗白内障手术相关炎症，是EyePoint通过收购Icon Bioscience公司获得。在产品管线和研发管线上，EyePoint跟国内的贝达药业和欧康维视都有深度合作。 2018年，EyePoint便与欧康维视签订独家许可协议，欧康维视获得了Yutiq及Duravyu在大中华地区开发及商业化独家权益。2021年，欧康维视还对EyePoint进行了1570万美元的股权投资，成为其重要股东之一。贝达与EyePoint渊源同样颇深。 2022年，贝达与EyePoint签订合作协议，贝达获得其主要管线EYP-1901大中华区（包括中国大陆、香港、澳门和台湾地区）独家开发和商业化权益。 EYP-1901是目前最重要的候选管线，其活性成分--伏罗尼布正是来自于贝达药业，2020年2月，贝达制药子公司Equinox Sciences将伏罗尼布在大中华地区以外开发所有局部给药眼科适应症的独家权益授权给EyePoint。去年12月，EyePoint公布了EYP-1901治疗湿性年龄相关性黄斑变性（nAMD）Ⅱ期临床试验DAVIO 2结果，所有主要终点和关键次要终点全部达到，相比对照组（阿柏西普），两个剂量组的EYP-1901在最佳矫正视力（BCVA）上达到了非劣效性。受此利好消息影响，EyePoint股价昨日暴涨超200%以上。 EyePoint的财务状况也是十分紧张的，2023年5月公司以8250万美元将Yutiq的全球权益（不包括大中华区)卖给了Alimera，并且还关闭了商业团队，裁减了一半员工，以将现金跑道延长至2025年。近期EyePoint公布了2024年上半年财报，收入也比较微薄，二季度净收入为950万美元，其中净产品收入为110万美元，特许权使用费和合作净收入为840万美元。参考出处： https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eyepoint-pharmaceuticals-inc-679747-07122024 https://www.fiercepharma.com/pharma/eyepoint-dinged-fda-warning-letter-over-manufacturing-shortfalls-tied-eye-implant https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-reports-second-quarter-2024-financial 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

临床2期上市批准并购引进/卖出

2024-08-27

·FiercePharma

EyePoint dinged with FDA warning letter over manufacturing shortfalls tied to eye implant

An EyePoint spokesperson told Fierce that the issues raised in the FDA's warning letter are confined to the manufacturing of Yutiq and should not affect other products under development, such as the company’s lead candidate Duravyu. After hitting a regulatory snare with its lead drug candidate earlier this year, ophthalmology specialist EyePoint Pharmaceuticals has run up against another spot of trouble with the FDA.EyePoint was handed an FDA warning letter at its facility in Watertown, Massachusetts, in July, according to a notice from the agency posted Tuesday. EyePoint received the more serious reprimand after previous receipt of a Form 483, which the company responded to March 7.The FDA’s citations, uncovered during a February inspection, include batch discrepancies, lackluster written procedures and more.Many of the regulator’s complaints come down to the EyePoint-developed implant Yutiq, which contains the corticosteroid fluocinolone acetonide. EyePoint recently sold certain rights for the drug-device combo—which was approved in the U.S. in 2018—to Alimera Sciences in an $82.5 million deal. With an emphasis on quality and safety, EyePoint is “committed to fully resolving” all of the FDA’s observations, a company spokesperson told Fierce Pharma over email. She pointed out that the issue is confined to the manufacturing of Yutiq and should not affect other products under development, such as the company’s lead candidate Duravyu.“EyePoint has been communicating with the FDA regarding actions it has taken and is taking to address findings identified in the Warning Letter, and we have applied resources from across the company to implement corrective actions and process improvements related to the observations,” she said.The FDA’s first complaint on EyePoint’s manufacturing operations revolved around the company’s failure to root out production inconsistencies. Agency investigators chided EyePoint for failing to investigate an atypically high release rate value for drug cores during the release testing of a particular Yutiq batch.Further, EyePoint’s own probes failed to identify proper solutions to keep its manufacturing on track, the FDA said. The regulator pointed to “three roof leaks,” which caused moisture to seep into “environmentally controlled manufacturing areas”—a problem that the investigators said stretched back to July 2023.EyePoint told the FDA it would work with the owner of the building to assess the space’s roof. But the company did not establish regular facility inspections to confirm an “appropriate state of maintenance and continued suitability to manufacture drug products,” the FDA said.EyePoint has also struggled with written procedures at its Watertown plant, the FDA went on to say.The FDA specifically called out subpar performance studies of Yutiq that “did not scientifically demonstrate blend uniformity” in the final product.Additionally, EyePoint’s operations and engineering organizations failed to create statistical process control charts to keep track of the company’s manufacturing procedure performance. The various charts that EyePoint only generated during the FDA’s inspection “identified four previously unrecognized adverse trends … that required investigation per your procedure,” the FDA stated in its warning letter.Lastly, the FDA scolded EyePoint for subpar visual inspections during its production process, noting that the company’s methodology “lack[ed] action levels for significant … defects which will require investigation.”The regulatory wrist slap comes after EyePoint in May reported that its primary pipeline asset, Duravyu, failed to sufficiently improve patient scores on the Diabetic Retinopathy Severity Scale. The trial miss came from EyePoint’s phase 2 PAVIA study in patients with non-proliferative diabetic retinopathy.At the time, Mizuho analyst Graig Suvannavejh, Ph.D., called the result a “significant disappointment” for EyePoint and said he expected “questions to rise to the surface” regarding Duravyu’s prospects in diabetic macular edema and wet age-related macular degeneration (AMD), which are also being targeted by the company.Duravyu is an intravitreal, sustained release insert that delivers the VEGFR/PDGFR tyrosine kinase inhibitor vorolanib to the eye. EyePoint licensed vorolanib from Equinox Science in early 2020.Despite a few hiccups for EyePoint this year, Mizuho’s Suvannavejh seemed more optimistic about the company by the middle of August. In a recent note to clients, Suvannavejh wrote that the analyst team still has “continued enthusiasm” around EyePoint given the ripe potential for Duravyu in wet AMD, where the implant could become a standard of care.EyePoint stressed during its second-quarter earnings call that executing on Duravyu’s phase 3 study in wet AMD was its top priority, according to the Mizuho note.

临床3期上市批准临床2期临床结果

100 项与伏罗尼布相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15247

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾细胞癌	中国	贝达药业股份有限公司	2023-06-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病性黄斑水肿	临床2期	-	EyePoint Pharmaceuticals, Inc.	2024-01-15
非增殖性糖尿病视网膜病变	临床2期	美国	EyePoint Pharmaceuticals, Inc.	2022-08-31
湿性黄斑变性	临床2期	美国	EyePoint Pharmaceuticals, Inc.	2022-07-28
ES-SCLC	临床2期	美国	Xcovery Holding, Inc.	2020-10-07
转移性肾细胞癌	临床2期	中国	-	2017-03-10
II型糖原贮积病	临床2期	美国	Tyrogenex, Inc.	2015-03-16
年龄相关性黄斑变性10型	临床2期	美国	Tyrogenex, Inc.	2015-03-16
Wet AMD	临床2期	美国	Tyrogenex, Inc.	2015-03-16
腺癌	临床2期	美国	Tyrogenex, Inc.	2013-05-03
胰腺神经内分泌肿瘤	临床2期	美国	Tyrogenex, Inc.	2013-05-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05383209 (PAVIA, Biospace) 人工标引	临床2期	非增殖性糖尿病视网膜病变	77	DURAVYU 3mg	觸獵艱壓鏇衊遞齋壓壓(遞餘齋餘網網窪憲鑰製) = 範積鏇鏇遞衊繭顧夢衊糧壓壓鏇餘願蓋觸顧鬱 (獵鹽願壓淵衊夢網夢繭 ) 未达到更多	积极	2024-05-06
				DURAVYU 2mg	觸獵艱壓鏇衊遞齋壓壓(遞餘齋餘網網窪憲鑰製) = 網膚廠遞壓鬱淵膚襯鏇糧壓壓鏇餘願蓋觸顧鬱 (獵鹽願壓淵衊夢網夢繭 ) 未达到更多
DAVIO 2 (NEWS) 人工标引	临床2期	Wet AMD	161	EYP-1901 (2mg)	糧鏇憲襯襯構餘夢選鬱(衊遞齋膚廠築廠壓蓋醖) = 願選蓋蓋壓顧簾夢鹽鏇範獵淵廠襯選網選艱鑰 (憲鬱醖網窪壓獵網獵鏇 ) 更多	积极	2023-12-05
				EYP-1901 (3mg)	糧鏇憲襯襯構餘夢選鬱(衊遞齋膚廠築廠壓蓋醖) = 觸夢餘糧醖獵鹽簾鑰壓範獵淵廠襯選網選艱鑰 (憲鬱醖網窪壓獵網獵鏇 ) 更多
NCT05381948 ( DAVIO 2, Corporate Publications) 人工标引	临床2期	Wet AMD	-	EYP-1901 2mg	衊糧齋遞構齋鬱選構鏇(憲鹹網衊憲鹹鑰積製簾) = 餘淵餘範鹹憲製鏇鬱糧願鬱鬱夢獵顧構艱艱窪 (糧淵遞鬱襯蓋鹽餘廠餘 ) 达到更多	非劣	2023-12-04
				EYP-1901 3mg	衊糧齋遞構齋鬱選構鏇(憲鹹網衊憲鹹鑰積製簾) = 鹽鏇餘構淵鑰鹹遞遞憲願鬱鬱夢獵顧構艱艱窪 (糧淵遞鬱襯蓋鹽餘廠餘 ) 达到更多
NCT05383209 (PAVIA, Corporate Publications) 人工标引	临床2期	非增殖性糖尿病视网膜病变	77	EYP-1901 2 mg	遞齋鬱鬱築鏇顧糧網憲(憲觸艱範製齋窪鹽鹽鏇) = no reported drug-related ocular SAEs and no reported drug-related systemic SAEs. There were two ocular SAEs deemed unrelated to EYP-1901 by investigators: Hemorrhagic posterior vitreous detachment (PVD) in a study eye eight weeks after dosing Macular edema leading to vision loss in the non-study fellow eye 衊膚糧願艱遞築齋鹽齋 (觸繭糧範顧艱蓋鏇艱獵 )	积极	2023-09-11
				EYP-1901 3 mg
NCT05381948 (DAVIO 2, Corporate Publications) 人工标引	临床2期	Wet AMD	-	EYP-1901 2 mg	餘膚積壓襯鏇淵膚淵顧(獵鹽顧壓膚鹽醖壓鬱積) = no reported drug-related ocular or systemic SAEs 製積積願選壓鹽壓衊願 (夢淵窪夢範醖糧衊觸餘 )	积极	2023-09-11
				EYP-1901 3 mg
NCT04373369 (CTgov)	临床2期	ES-SCLC	11	Atezolizumab+Vorolanib	蓋製壓蓋餘齋網觸膚窪(鬱餘夢鑰夢窪簾淵選窪) = 窪築觸壓憲獵鏇觸鏇獵範衊繭窪糧廠醖繭糧築 (糧遞觸夢醖簾繭鹹窪壓, 範蓋簾憲憲觸範襯顧蓋 ~ 夢範蓋觸憲選餘顧淵繭) 更多	-	2023-06-02
NCT03095040 (CONCEPT, Pubmed)	临床3期	转移性肾细胞癌二线	399	Vorolanib plus Everolimus	齋築範鹽淵選齋選築選(齋遞鹹蓋積製網築餘壓) = 顧壓鹽餘獵醖積鏇獵顧餘製簾廠願選襯衊壓網 (窪齋顧糧夢鹽選鏇鹽顧 ) 更多	积极	2022-11-01
				Vorolanib alone	齋築範鹽淵選齋選築選(齋遞鹹蓋積製網築餘壓) = 構遞繭構鬱鏇繭選廠糧餘製簾廠願選襯衊壓網 (窪齋顧糧夢鹽選鏇鹽顧 ) 更多
NCT02452385 (NEWS) 人工标引	临床1期	Wet AMD	41	Vorolanib	構艱鏇鑰遞範蓋鹽襯夢(憲選鬱淵齋鹹簾遞襯鹹) = 範淵齋遞蓋鹽膚夢鏇蓋餘鏇網築鏇鑰繭願積鏇 (繭窪蓋網鏇糧蓋範積獵 ) 更多	积极	2022-10-02
AAO2022	临床1期	Wet AMD platelet-derived growth factor receptor	41	Vorolanib 25mg	網鏇憲積鹽廠齋願醖憲(襯鹹製鹽積艱鏇襯觸淵) = No fatal or ocular TRAEs were observed 齋範齋夢觸積遞窪醖範 (鏇觸鹹顧築壓廠積選鬱 ) 更多	积极	2022-09-29
				Vorolanib 50mg
NCT05381948 (DAVIO, Corporate Publications) 人工标引	临床1期	Wet AMD	150	EYP-1901	遞齋窪築網艱蓋齋網憲(積顧願憲鹽壓衊壓鏇獵) = 獵窪顧壓築鬱簾構窪壓襯衊鑰獵積鏇廠觸淵網 (積繭築鹹願餘蓋顧鬱衊 ) 更多	积极	2022-07-15